专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20160213734A1 PROCESS FOR MANUFACTURING GLATIRAMER ACETATE PRODUCT 审中-公开
标题翻译：制备玻璃酸乙酯产品的方法
公开(公告)号：US20160213734A1
公开(公告)日：2016-07-28
申请号：US14860053
申请日：2015-09-21
申请人： Rakefet Cohen , Sasson Habbah , Muhammad Safadi
发明人： Rakefet Cohen , Sasson Habbah , Muhammad Safadi
IPC分类号： A61K38/02 , A61K9/08 , A61K9/00 , A61K47/26
CPC分类号： A61K38/02 , A61K9/0019 , A61K9/08 , A61K38/03 , A61K38/16 , A61K47/26
摘要： The patent provides a process of preparing a pharmaceutical preparation of glatiramer acetate and mannitol in a suitable container comprising the steps of: (i) obtaining an aqueous pharmaceutical solution of glatiramer acetate and mannitol; (ii) filtering the aqueous pharmaceutical solution at a temperature of from above 0° C. up to 17.5° C. to produce a filtrate; and (iii) filling the suitable container with the filtrate obtained after performing step (ii), so as to thereby prepare the pharmaceutical preparation of glatiramer acetate and mannitol in the suitable container. This patent further provides an aqueous pharmaceutical solution comprising 40 mg/ml glatiramer acetate and 40 mg/ml mannitol, wherein the aqueous pharmaceutical solution a) has a viscosity in the range of 2.0-3.5 cPa; or b) has an osmolality in the range of 275-325 mosmol/Kg. This patent also provides a prefilled syringe, an automated injector and a method of treatment of a human patient.
摘要翻译：该专利提供了在合适的容器中制备乙酸格拉默和甘露糖醇的药物制剂的方法，包括以下步骤：（i）获得乙酸格拉默和甘露醇的药物水溶液; （ii）在高于0℃至17.5℃的温度下过滤药物水溶液以产生滤液; 和（iii）在进行步骤（ii）之后用所得滤液填充合适的容器，从而在合适的容器中制备乙酸格拉默和甘露糖醇的药物制剂。该专利还提供了包含40mg / ml醋酸格拉默和40mg / ml甘露醇的药物水溶液，其中药物水溶液a）的粘度范围为2.0-3.5cPa; 或b）的重量摩尔渗透压浓度范围为275-325 mosmol / Kg。该专利还提供预充式注射器，自动注射器和治疗人类患者的方法。

2. 发明申请

US20140024678A1 STABLE LAQUINIMOD PREPARATIONS 审中-公开
标题翻译：稳定的液体制剂
公开(公告)号：US20140024678A1
公开(公告)日：2014-01-23
申请号：US14032425
申请日：2013-09-20
申请人： Muhammad Safadi , Daniella Licht , Ioana Lovinger , Aharon M. Eyal , Tomas Fristedt , Karl Jansson
发明人： Muhammad Safadi , Daniella Licht , Ioana Lovinger , Aharon M. Eyal , Tomas Fristedt , Karl Jansson
IPC分类号： A61K31/4704 , C07D471/10 , B65B25/00 , C07D209/34
CPC分类号： B65B25/00 , A61K9/1623 , A61K9/2004 , A61K9/2018 , A61K31/438 , A61K31/4704 , C07D209/34 , C07D209/42 , C07D471/10 , Y10T436/145555
摘要： The subject invention provides a pharmaceutical composition comprising N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5- chloro-1-methyl-2-oxoquinoline-3-carboxamide or the salt thereof; a pharmaceutically acceptable carrier; and not more than 0.5% w/w relative to N-ethyl-N-phenyl-1,2,-dihydro-4 -hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide of 2-Chloro-6-(1-ethyl-N-methyl-2-oxoindoline-3-carboxamido) benzoic acid, 1H,3H-spiro[5-chloro-1-methylquinoline-2,4 -dione-3,3′-[1]ethylindolin-[2]-one], or 5-Chloro-N-ethyl-3-hydroxy-1-methyl-2,4-dioxo-N-phenyl-1,2,3,4 -tetrahydro-quinoline-3-carboxamide.
摘要翻译：本发明提供包含N-乙基-N-苯基-1,2-二氢-4-羟基-5-氯-1-甲基-2-氧代喹啉-3-甲酰胺或其盐的药物组合物; 药学上可接受的载体; 并且相对于2-氯 - 苯基-1,2-二氢-4-羟基-5-氯-1-甲基-2-氧代喹啉-3-甲酰胺，相对于N-乙基-N-苯基-1,2-二氢-4-羟基-5-氯-1-甲基-2-氧代喹啉-3-甲酰胺为0.5％w / 6-（1-乙基-N-甲基-2-氧代二氢吲哚-3-甲酰氨基）苯甲酸，1H，3H-螺[5-氯-1-甲基喹啉-2,4-二酮-3,3' - [1] 乙基吲哚并[2] - 酮]或5-氯-N-乙基-3-羟基-1-甲基-2,4-二氧代-N-苯基-1,2,3,4-四氢 - 甲酰胺。

3. 发明申请

US20130217724A1 N-ETHYL-N-PHENYL-1,2-DIHYDRO-4,5-DI-HYDROXY-1-METHYL-2-OXO-3-QUINOLINECARBOXAMIDE, PREPARATION AND USES THEREOF 有权
标题翻译： N-乙基-N-苯基-1,2-二氢-4,5-二羟基-1-甲基-2-氧代-3-喹啉甲酰胺，其制备及其用途
公开(公告)号：US20130217724A1
公开(公告)日：2013-08-22
申请号：US13768919
申请日：2013-02-15
申请人： Vladimir Ioffe , Konstantin Ulanenko , Avital Laxer , Muhammad Safadi , Danit Licht , Ioana Lovinger , Ulf Tomas Fristedt
发明人： Vladimir Ioffe , Konstantin Ulanenko , Avital Laxer , Muhammad Safadi , Danit Licht , Ioana Lovinger , Ulf Tomas Fristedt
IPC分类号： C07D215/56 , A61J1/03 , A61K31/4704
CPC分类号： A61K31/4704 , A61J1/035 , A61K9/20 , A61K9/2813 , A61K9/48 , A61K9/4891 , B65D1/0207 , B65D41/04 , B65D41/0407 , B65D50/00 , B65D51/24 , B65D81/264 , C07D215/56
摘要： The subject invention provides a pharmaceutical composition containing laquinimod or a pharmaceutically acceptable salt thereof, and a compound of N-ethyl-N-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinolinecarboxamide or a salt thereof.
摘要翻译：本发明提供含有拉喹莫德或其药学上可接受的盐的药物组合物和N-乙基-N-苯基-1,2-二氢-4,5-二羟基-1-甲基-2-氧代 - 3-喹啉甲酰胺或其盐。

4. 发明申请

US20100189791A1 Delayed release rasagiline malate formulation 审中-公开
标题翻译：延迟释放雷沙吉兰苹果酸盐配方
公开(公告)号：US20100189791A1
公开(公告)日：2010-07-29
申请号：US12456001
申请日：2009-06-09
申请人： Muhammad Safadi , Daniella Licht , Rachel Cohen , Anton Frenkel , Marina Zholkovsky
发明人： Muhammad Safadi , Daniella Licht , Rachel Cohen , Anton Frenkel , Marina Zholkovsky
IPC分类号： A61K9/36 , A61K31/136
CPC分类号： A61K9/2893 , A61K9/2013 , A61K9/2018 , A61K9/2054 , A61K9/2059 , A61K9/2846 , A61K9/2886 , A61K31/135 , C07C59/265 , C07C211/42 , C07C2602/08
摘要： Disclosed are formulations which are designed to delay release of rasagiline while maintaining specific pharmacokinetic properties.
摘要翻译：公开了旨在延迟雷沙吉兰释放同时保持特定药代动力学性质的制剂。

5. 发明申请

US20090181086A1 Rasagiline formulations, their preparation and use 审中-公开
标题翻译：雷沙吉兰配方，其制备和用途
公开(公告)号：US20090181086A1
公开(公告)日：2009-07-16
申请号：US12319576
申请日：2009-01-09
申请人： Muhammad Safadi , Daniella Licht , Rachel Cohen
发明人： Muhammad Safadi , Daniella Licht , Rachel Cohen
IPC分类号： A61K9/62 , A61K9/00 , A61K9/28 , A61K9/32
CPC分类号： A61K9/2846
摘要： Disclosed are formulations which are designed to release rasagiline mesylate while maintaining specific pharmacokinetic properties.
摘要翻译：公开了旨在释放甲磺酸雷沙吉兰同时保持特定药代动力学性质的制剂。

6. 发明申请

US20160151346A1 N-ETHYL-N-PHENYL-1,2-DIHYDRO-4,5-DI-HYDROXY-1-METHYL-2-OXO-3-QUINOLINECARBOXAMIDE, PREPARATION AND USES THEREOF 审中-公开
公开(公告)号：US20160151346A1
公开(公告)日：2016-06-02
申请号：US15013633
申请日：2016-02-02
申请人： Vladimir Ioffe , Konstantin Ulanenko , Avital Laxer , Muhammad Safadi , Danit Licht , Ioana Lovinger , Ulf Tomas Fristedt
发明人： Vladimir Ioffe , Konstantin Ulanenko , Avital Laxer , Muhammad Safadi , Danit Licht , Ioana Lovinger , Ulf Tomas Fristedt
IPC分类号： A61K31/4704 , B65D50/00 , B65D41/04 , A61J1/03 , B65D1/02
CPC分类号： A61K31/4704 , A61J1/035 , A61K9/20 , A61K9/2813 , A61K9/48 , A61K9/4891 , B65D1/0207 , B65D41/04 , B65D41/0407 , B65D50/00 , B65D51/24 , B65D81/264 , C07D215/56
摘要： The subject invention provides a pharmaceutical composition containing laquinimod or a pharmaceutically acceptable salt thereof, and a compound of N-ethyl-N-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinolinecarboxamide or a salt thereof.

7. 发明授权

US09155775B1 Process for manufacturing glatiramer acetate product 有权
标题翻译：制造醋酸格拉醋酸酯产品的方法
公开(公告)号：US09155775B1
公开(公告)日：2015-10-13
申请号：US14608126
申请日：2015-01-28
申请人： Rakefet Cohen , Sasson Habbah , Muhammad Safadi
发明人： Rakefet Cohen , Sasson Habbah , Muhammad Safadi
IPC分类号： A61K38/02
CPC分类号： A61K38/02 , A61K9/0019 , A61K9/08 , A61K38/03 , A61K38/16 , A61K47/26
摘要： The patent provides a process of preparing a pharmaceutical preparation of glatiramer acetate and mannitol in a suitable container comprising the steps of: (i) obtaining an aqueous pharmaceutical solution of glatiramer acetate and mannitol; (ii) filtering the aqueous pharmaceutical solution at a temperature of from above 0° C. up to 17.5° C. to produce a filtrate; and (iii) filling the suitable container with the filtrate obtained after performing step (ii), so as to thereby prepare the pharmaceutical preparation of glatiramer acetate and mannitol in the suitable container. This patent further provides an aqueous pharmaceutical solution comprising 40 mg/ml glatiramer acetate and 40 mg/ml mannitol, wherein the aqueous pharmaceutical solution a) has a viscosity in the range of 2.0-3.5 cPa; or b) has an osmolality in the range of 275-325 mosmol/Kg. This patent also provides a prefilled syringe, an automated injector and a method of treatment of a human patient.
摘要翻译：该专利提供了在合适的容器中制备乙酸格拉默和甘露糖醇的药物制剂的方法，包括以下步骤：（i）获得乙酸格拉默和甘露醇的药物水溶液; （ii）在高于0℃至17.5℃的温度下过滤药物水溶液以产生滤液; 和（iii）在进行步骤（ii）之后用所得滤液填充合适的容器，从而在合适的容器中制备乙酸格拉默和甘露糖醇的药物制剂。该专利还提供了包含40mg / ml醋酸格拉默和40mg / ml甘露醇的药物水溶液，其中药物水溶液a）的粘度范围为2.0-3.5cPa; 或b）的重量摩尔渗透压浓度范围为275-325 mosmol / Kg。该专利还提供预充式注射器，自动注射器和治疗人类患者的方法。

8. 发明申请

US20100189790A1 Delayed release rasagiline formulation 审中-公开
标题翻译：延迟释放雷沙吉兰配方
公开(公告)号：US20100189790A1
公开(公告)日：2010-07-29
申请号：US12456029
申请日：2009-06-09
申请人： Muhammad Safadi , Daniella Licht , Rachel Cohen , Anton Frenkel , Marina Zholkovsky
发明人： Muhammad Safadi , Daniella Licht , Rachel Cohen , Anton Frenkel , Marina Zholkovsky
IPC分类号： A61K9/30 , A61P25/16
CPC分类号： A61K9/2893 , A61K9/2013 , A61K9/2018 , A61K9/2054 , A61K9/2059 , A61K9/2846 , A61K9/2886 , A61K31/135 , C07C59/265 , C07C211/42 , C07C2602/08
摘要： Disclosed are formulations which are designed to delay release of rasagiline while maintaining specific pharmacokinetic properties.
摘要翻译：公开了旨在延迟雷沙吉兰释放同时保持特定药代动力学性质的制剂。

9. 发明申请

US20180036363A1 PROCESS FOR MANUFACTURING GLATIRAMER ACETATE PRODUCT 审中-公开
公开(公告)号：US20180036363A1
公开(公告)日：2018-02-08
申请号：US15788698
申请日：2017-10-19
申请人： Rakefet Cohen , Sasson Habbah , Muhammad Safadi
发明人： Rakefet Cohen , Sasson Habbah , Muhammad Safadi
IPC分类号： A61K38/02 , A61K9/00 , A61K9/08 , A61K47/26 , A61K38/16
摘要： The patent provides a process of preparing a pharmaceutical preparation of glatiramer acetate and mannitol in a suitable container comprising the steps of: (i) obtaining an aqueous pharmaceutical solution of glatiramer acetate and mannitol; (ii) filtering the aqueous pharmaceutical solution at a temperature of from above 0° C. up to 17.5° C. to produce a filtrate; and (iii) filling the suitable container with the filtrate obtained after performing step (ii), so as to thereby prepare the pharmaceutical preparation of glatiramer acetate and mannitol in the suitable container. This patent further provides an aqueous pharmaceutical solution comprising 40 mg/ml glatiramer acetate and 40 mg/ml mannitol, wherein the aqueous pharmaceutical solution a) has a viscosity in the range of 2.0-3.5 cPa; or b) has an osmolality in the range of 275-325 mosmol/Kg. This patent also provides a prefilled syringe, an automated injector and a method of treatment of a human patient.

10. 发明申请

US20170065576A1 N-ETHYL-N-PHENYL-1,2-DIHYDRO-4,5-DI-HYDROXY-1-METHYL-2-OXO-3-QUINOLINECARBOXAMIDE, PREPARATION AND USES THEREOF 审中-公开
标题翻译： N-乙基-N-苯基-1,2-二氢-4,5-二羟基-1-甲基-2-氧代-3-喹啉甲酰胺，其制备及其用途
公开(公告)号：US20170065576A1
公开(公告)日：2017-03-09
申请号：US15354836
申请日：2016-11-17
申请人： Vladimir Ioffe , Konstantin Ulanenko , Avital Laxer , Muhammad Safadi , Danit Licht , Ioana Lovinger , Ulf Tomas Fristedt
发明人： Vladimir Ioffe , Konstantin Ulanenko , Avital Laxer , Muhammad Safadi , Danit Licht , Ioana Lovinger , Ulf Tomas Fristedt
IPC分类号： A61K31/4704 , A61K9/20 , B65D81/26 , B65D1/02 , B65D41/04 , B65D51/24 , A61K9/48 , A61J1/03
CPC分类号： A61K31/4704 , A61J1/035 , A61K9/20 , A61K9/2813 , A61K9/48 , A61K9/4891 , B65D1/0207 , B65D41/04 , B65D41/0407 , B65D50/00 , B65D51/24 , B65D81/264 , C07D215/56
摘要： The subject invention provides a pharmaceutical composition containing laquinimod or a pharmaceutically acceptable salt thereof, and a compound of N-ethyl-N-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinolinecarboxamide or a salt thereof.
摘要翻译：本发明提供含有拉喹莫德或其药学上可接受的盐的药物组合物和N-乙基-N-苯基-1,2-二氢-4,5-二羟基-1-甲基-2-氧代 - 3-喹啉甲酰胺或其盐。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式